Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $28.9 million.

  • Crinetics Pharmaceuticals' Accumulated Expenses rose 23.70% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 23.70%. This contributed to the annual value of $28.9 million for FY2024, which is 98.99% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Accumulated Expenses of $28.9 million as of FY2024, which was up 98.99% from $14.5 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Accumulated Expenses high stood at $28.9 million for FY2024, and its period low was $4.1 million during FY2020.
  • In the last 3 years, Crinetics Pharmaceuticals' Accumulated Expenses had a median value of $14.5 million in 2023 and averaged $17.5 million.
  • Data for Crinetics Pharmaceuticals' Accumulated Expenses shows a peak YoY soared of 98.99% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Accumulated Expenses stood at $4.1 million in 2020, then skyrocketed by 62.03% to $6.6 million in 2021, then spiked by 37.84% to $9.1 million in 2022, then skyrocketed by 59.86% to $14.5 million in 2023, then skyrocketed by 98.99% to $28.9 million in 2024.